Senior Analyst at Innovis VC
Sourced and analyzed 100+ early-stage startups across Europe for Speedinvest, Earlybird, and Cherry Ventures. Two years building a view of European deep tech at deal-flow scale.
Early-Stage Investor · Corporate Finance · AI & Deep Tech
Hi, I'm Alessandro. Building a career in early-stage venture capital, investing in AI and deep tech. I also work with a small number of founders as an advisor on finance, fundraising, and strategy.
My journey started at Bocconi, where I studied Economics and Finance. During university, I co-founded Main21 while spending two years at Innovis VC sourcing early-stage startups for Speedinvest, Earlybird, and Cherry Ventures.
After graduating, I joined Bocconi's B4i Future Founders Programme to build Promethiq — at that point I still wanted to be a founder, and B4i offered the structured environment to take that shot properly. From there, I joined Startup Geeks, a startup and incubator, as analyst and AI lead, advising over 30 early-stage founders on go-to-market, fundraising, and strategy.
Through that work, I realized I came alive when evaluating opportunities, structuring deals, and reading markets — and when supporting founders strategically with what I'd learned from building my own companies. That pull was clearly toward investing, not operating.
So I joined Quantyx as a Corporate Finance & Valuation Analyst, where I work on valuations of VC and PE funds and dig into the financial structure of their portfolio companies. More recently, I joined FNDX, where I work on M&A and operations on Velta Capital, a buy-and-build platform. Alongside this, I scout for Flashpoint (international tech VC fund, London based, ~$600M AUM), advise early-stage startups on finance, fundraising, and strategy, and invest as an angel.
Sourced and analyzed 100+ early-stage startups across Europe for Speedinvest, Earlybird, and Cherry Ventures. Two years building a view of European deep tech at deal-flow scale.
Valuations of Venture Capital and Private Equity funds, with deep financial analysis of portfolio companies across European tech.
Sourcing growth-stage B2B technology companies founded by European or Israeli entrepreneurs to one of Flashpoint's three investment strategies: Venture Growth, Growth Debt, and Direct Secondary.
M&A, operations and fundraising on Velta Capital, a buy-and-build platform.
I make small angel investments in companies whose thesis I want to follow closely. The portfolio below is small and selective.
My focus is B2B AI in regulated, data-heavy industries — pharma, healthcare, financial services — and deep tech adjacent to AI like synthetic biology and scientific tooling. I look for companies where AI makes something ten times faster or cheaper, where the moat is data access or operational depth rather than model architecture, and where founders understand the industry they're disrupting from the inside.
AI safety and research company building large language models, with Claude as its flagship product. Founded in 2021 by former OpenAI researchers, focused on capability and safety research with emphasis on interpretability and Constitutional AI.
Paris-based AI healthtech building benefit-risk intelligence for pharmaceutical drug development. Its platform integrates 100B+ biomedical data points and 24 specialized AI models, working with 10+ pharma clients including Sanofi, AstraZeneca, and GSK. Raised a $7M seed round in 2025.
San Francisco-based company building foundation models that generate missing patient bio-data for pharmaceutical drug development. Their multimodal model predicts spatial proteomics from routine H&E staining — beating state-of-the-art in under 6 weeks. Helps pharma select better patients for clinical trials, addressing the $60-100B spent annually on trials that fail.
Essays on technology, capital, and how the future gets built. Published on DeepFrontier (Substack): https://alessandroromeri.substack.com
Reframes economics and entrepreneurship around a single question: where does wealth actually come from? Dismantles the zero-sum myth and builds a case for wealth creation as positive-sum, innovation-driven. Draws on Paul Graham, Schumpeter, Hayek, and Kirzner to show how startups, technology, and entrepreneurial discovery expand human capability rather than reallocate fixed resources. Themes: creative destruction, network effects, effectual reasoning, increasing returns, and the moral distinction between creation and extraction.
On the dangers of default thinking, binary mental models, and rigid societal scripts, and the case for cultivating intellectual independence. Draws on Emerson, Bezos, Fitzgerald, Hayek, and Saras Sarasvathy to argue for first principles thinking, vision crafting, and mental independence over inherited scripts.
On the convergence of AI and synthetic biology. Centered around Nvidia and the Arc Institute's Evo 2, covers AI-generated DNA sequences, protein design, AI-enhanced CRISPR, and the funding boom from a16z and Flagship — plus the philosophical and regulatory questions around engineering biology.
How AI is reshaping how startups raise capital and how investors allocate it. Covers automated VC funds, AI-powered deal flow, and real-time investment algorithms from EQT's Motherbrain to SignalFire's Beacon AI — and the risks of bias, missed outliers, and the loss of contrarian human intuition.
Books that have shaped how I think about capital, technology, history, human behavior, and decision-making.
Open to conversations about early-stage investing, deal flow, and capital allocation. Best reached by email or LinkedIn.